| Literature DB >> 29674311 |
Eyal Karin1, Blake F Dear1,2, Gillian Z Heller3, Monique F Crane4, Nickolai Titov1,2.
Abstract
BACKGROUND: Missing cases following treatment are common in Web-based psychotherapy trials. Without the ability to directly measure and evaluate the outcomes for missing cases, the ability to measure and evaluate the effects of treatment is challenging. Although common, little is known about the characteristics of Web-based psychotherapy participants who present as missing cases, their likely clinical outcomes, or the suitability of different statistical assumptions that can characterize missing cases.Entities:
Keywords: missing data; psychotherapy; statistical bias; treatment adherence and compliance; treatment efficacy
Year: 2018 PMID: 29674311 PMCID: PMC5938693 DOI: 10.2196/mental.8363
Source DB: PubMed Journal: JMIR Ment Health ISSN: 2368-7959
Demographic and clinical sample characteristics. GAD-7: Generalized Anxiety Disorder Scale 7-item; N/A: not applicable; PHQ-9: Patient Health Questionnaire 9-item.
| Characteristics | Total sample collated, value (n=820) | Completersa, value (n=682) | Missing casesb, value (n=138) | Recontacted casesc, value (n=55) | |||||
| Female | 606 (73.9) | 465 (75.2) | 95 (68.8) | 39 (71) | |||||
| Male | 214 (26.1) | 153 (24.8) | 43 (31.2) | 16 (29) | |||||
| Age, mean (SD) | 43.2 (11.1) | 44.1 (11.4) | 40.4 (11.1) | 38.1 (11.4) | |||||
| Completed (1 of 5) | 65 (7.9) | 9 (1.5) | 49 (35.5) | 14 (25) | |||||
| Completed (2 of 5) | 53 (6.5) | 26 (4.2) | 24 (17.4) | 6 (11) | |||||
| Completed (3 of 5) | 76 (9.3) | 39 (6.3) | 23 (16.7) | 13 (24) | |||||
| Completed (4 of 5) | 145 (17.7) | 101 (16.3) | 22 (15.9) | 10 (18) | |||||
| Completed all modules | 481 (58.7) | 443 (71.7) | 20 (14.5) | 12 (22) | |||||
| Otherwise | 306 (37.3) | 215 (34.8) | 62 (44.9) | 23 (42) | |||||
| In a relationship | 514 (62.7) | 403 (65.2) | 76 (55.1) | 32 (58) | |||||
| Non-tertiary | 356 (43.4) | 254 (41.1) | 71 (51.4) | 26 (47) | |||||
| Tertiary | 464 (56.6) | 364 (58.9) | 67 (48.6) | 29 (53) | |||||
| GAD-7 baseline, mean (SD) | 11.3 (4.6) | 11.0 (4.6) | 12.0 (4.6) | 11.9 (4.8) | |||||
| PHQ-9 baseline, mean (SD) | 12.3 (4.7) | 11.9 (4.8) | 13.9 (4.4) | 13.7 (4.5) | |||||
| None | 345 (42.1) | 277 (44.8) | 44 (31.9) | 17 (31) | |||||
| Comorbid | 475 (57.9) | 341 (55.2) | 94 (68.1) | 38 (69) | |||||
| Missing at posttreatment, n (%) | 138 (16.8) | N/Ad | N/A | 55 (40) | |||||
| Missing at follow-up, n (%) | 147 (17.9) | N/A | N/A | N/A | |||||
aIndividuals that completed all surveys.
bIndividuals with any missing posttreatment data.
cIndividuals recontacted at 3-month follow-up (n=55).
dN/A: not applicable.
Logistical regression model testing for predictor of missing cases of posttreatment. GAD-7: Generalized Anxiety Disorder Scale 7-item; PHQ-9: Patient Health Questionnaire 9-item.
| Predictors of missing values | Univariate models | Multivariate models ( | |||||||
| Odds ratio | Percentage of missing casesb | Variance explained, % | Percentage of missing casesb | Variance explained, | |||||
| — | — | ||||||||
| Age (% per year) | <.001 | 0.97 | −3 (−2 to −5] | 3 | |||||
| — | — | ||||||||
| Female | .14 | 16 (13-19) | |||||||
| Male | 0.74 | 20 (15 to 20) | <1 | ||||||
| — | — | ||||||||
| In a relationship | .04 | 15 (12 to 18) | |||||||
| Otherwise | 1.46 | 20 (16 to 25) | 1 | ||||||
| — | — | ||||||||
| Tertiary education | .047 | 14 (12 to 18) | |||||||
| Otherwise | 1.48 | 20 (16 to 24) | 1 | ||||||
| 0 (0 to 0) | |||||||||
| Baseline anxiety symptoms (% per GAD-7 point) | .03 | 1.05 | 5 (0.5 to 9) | 1 | — | — | |||
| Baseline depression symptoms (% per PHQ-9 point) | <.001 | 1.09 | 9 (5 to 14)c | 4 | .002 | 8 (3 to 14)c | 40 | ||
| Comorbidity at baseline: (PHQ-9≥10 and GAD-7≥8) | .01 | 20 (16 to 24) | — | — | |||||
| None | 0.59 | 13 (10 to 17) | 2 | ||||||
| Completed all modules | <.001 | 4 (3 to 6)c | 39 | 4 (3 to 6)c | 40 | ||||
| Completed (4 of 5) | 4.12 | 15 (10 to 22) | <.001 | 14 (9 to 21) | |||||
| Completed (3 of 5) | 10 | 30 (21 to 41) | <.001 | 27 (18 to 38) | |||||
| Completed (2 of 5) | 19.08 | 45 (33 to 59) | <.001 | 42 (29 to 56) | |||||
| Completed (1 of 5) | 70.59 | 75 (64 to 84) | <.001 | 75 (63 to 84) | |||||
aAll models are based on a logistic regression model, including a log link function. Overall model accuracy for classification of missing values outcomes was 87.4%, with a specificity of 96.6% and sensitivity of 42%.
bPercentage of relative risk of an individual to become becoming missing at posttreatment.
cRelative odds of an individual to become a missing case with every additional unit increase.
Association of predictor variables with clinical symptom change from baseline. GAD-7: Generalized Anxiety Disorder Scale 7-item; GEE: generalized estimating equation; PHQ-9: Patient Health Questionnaire 9-item.
| Predictor of rate of clinical change | GEEa univariate models | Mixed univariate models | ||||||
| Moderation of symptom change (Time×IV) at posttreatment | Moderation of symptom change (Time×IV) at posttreatment | |||||||
| Wald chi-square | Percentage changeb,c | Percentage changeb,c | ||||||
| Age (years, % per year) | .03 | 7.1 (1) | −1 (0 to −2) | .007 | 1.8 (1,1071) | <1 (<1 to <1) | ||
| Female (versus male) | .43 | 1.7 (1) | .27 | 1.3 (1,1071) | ||||
| In a relationship (versus otherwise) | .21 | 3.2 (1) | .22 | 1.5 (1,1071) | ||||
| Tertiary (versus otherwise) | .17 | 3.5 (1) | .15 | 1.9 (1,1071) | ||||
| Baseline anxiety symptoms (% per GAD-7 point) | >.99 | 0.1 (1) | .98 | <0.1 (1,1071) | ||||
| Baseline depression symptoms (% per PHQ-9 point) | <.001 | 22.3 (1) | 2 (1 to 3) | <.001 | 11.6 (1,1071) | 2 (1 to 3) | ||
| Comorbidity at baseline: (PHQ-9≥10 and GAD-7≥8) | .16 | 3.6 (1) | .10 | 2.3 (1,1071) | ||||
| None | ||||||||
| <.001 | 39.0 (4) | <.001 | 3.6 (4,1071) | |||||
| Completed all modules | 49 (45 to 52) | 40 (16 to 56) | ||||||
| Completed (4 of 5) | 40 (32 to 47) | 29 (0 to 50) | ||||||
| Completed (3 of 5) | 46 (36 to 55) | 26 (−7 to 49) | ||||||
| Completed (2 of 5) | 42 (27 to 53) | 35 (2 to 57) | ||||||
| Completed (1 of 5) | 21 (−8 to 43) | 19 (−11 to 41) | ||||||
aAll models are based on a GEE model of change over time, interacting with a covariate.
bPercentage indication of a change from baseline.
cMarginal means reported for predictors with statistical significance (P<.05).
Figure 1Treatment adherence (competition out of five modules) and the likelihood of missing cases or symptom improvement from pretreatment levels (%); dotted lines illustrate 95% CI of the estimate. PHQ-9: Patient Health Questionnaire 9-item.
Figure 2Pretreatment Patient Health Questionnaire 9-item (PHQ-9) symptoms influencing likelihood of missing cases or symptom outcomes. The **-dotted line implies a sample size of <10 participants from the sample of 820.
Depression (Patient Health Questionnaire 9-item, PHQ-9) simulate (approximated) replacement scores—unadjusted (missing completely at random, MCAR) models, last observation carried forward (LOCF), and baseline observation carried forward (BOCF). GEE: generalized estimating equation; N/A: not applicable.
| Source of PHQ-9 estimates | Mean (95% CI) | Relative percentage accuracy from recontacted cases (95% CI) | Conclusion drawn about accuracya |
| Recontacted cases | 8.11 (6.53-10.07) | N/A | |
| BOCF | 13.75 (12.57-15.03) | 69 (55-85) | Significant overestimation |
| LOCF | 9.96 (8.65-11.48) | 24 (7-42) | Significant overestimation |
| MCAR (GEE) | 5.93 (5.58-6.3) | −27 (−22 to −31) | Significant underestimation |
| MCAR (mixed) | 5.96 (5.62-6.34) | −26 (−14 to −37) | Significant underestimation |
aRelative accuracy from observed recontacted cases following a clinical follow-up.
Depression (Patient Health Questionnaire 9-item; PHQ-9) simulate (approximated) replacement scores from various adjusted models. GAD-7: Generalized Anxiety Disorder Scale 7-item; GEE: generalized estimating equation; MAR: missing at random; N/A: not applicable.
| Source of PHQ-9 estimates | Mean score | Relative percentage accuracy from recontacted cases | Conclusion drawn about accuracya |
| Observed symptom score from recontacted cases | 8.11 (6.53-10.07) | N/A | N/A |
| MAR PHQ-9 baseline and treatment adherence (GEE) | 7.47 (6.84-8.15) | −8 (−16 to 0) | Statistical equivalence |
| MAR PHQ-9 baseline and treatment adherence (mixed) | 7.5 (6.89-8.16) | −8 (−19 to 6) | |
| MAR GAD-7 baseline and treatment adherence (GEE) | 7.15 (6.7-7.63) | −12 (−24 to 3) | Statistical equivalence |
| MAR GAD-7 baseline and treatment adherence (mixed) | 7.28 (6.81-7.78) | −10 (−23 to 4) | |
| MAR treatment adherence (GEE) | 6.91 (6.6-7.25) | −15 (−19 to −11) | Statistical equivalence |
| MAR treatment adherence (mixed) | 7.06 (6.71-7.43) | −13 (−26 to 3) | |
| MAR PHQ-9 baseline (GEE) | 6.57 (6.07-7.12) | −19 (−25 to −12) | Statistical equivalence |
| MAR PHQ-9 baseline (mixed) | 6.54 (6.05-7.07) | −19 (−30 to −7) | |
| MAR comorbidity and education, and age (GEE) | 6.31 (5.99-6.65) | −22 (−26 to −18) | Significant underestimation |
| MAR comorbidity and education, and age (mixed) | 6.33 (6.01-6.66) | −22 (−34 to −8) | |
| MAR comorbidity (GEE) | 6.23 (5.9-6.57) | −23 (−27 to −19) | Significant underestimation |
| MAR comorbidity (mixed) | 6.24 (5.93-6.58) | −23 (−35 to −9) | |
| MAR GAD-7 baseline (GEE) | 6.09 (5.82-6.37) | −25 (−28 to −21) | Significant underestimation |
| MAR GAD-7 baseline (mixed) | 6.12 (5.85-6.4) | −25 (−36 to −10) | |
| MAR age (GEE) | 6.03 (5.97-6.08) | −26 (−26 to −25) | Significant underestimation |
| MAR age (mixed) | 6.07 (6.01-6.13) | −25 (−39 to −8) | |
| MAR Marital Status (GEE) | 6 (5.83-6.17) | −26 (−28 to −24) | Significant underestimation |
| MAR marital Status (mixed) | 6.03 (5.87-6.2) | −26 (−38 to −10) | |
| MAR education (GEE) | 5.96 (5.88-6.04) | −27 (−28 to −26) | Significant underestimation |
| MAR education (mixed) | 5.99 (5.91-6.07) | −26 (−40 to −9) | |
| MAR gender (GEE) | 5.94 (5.89-6) | −27 (−27 to −26) | Significant underestimation |
| MAR gender (mixed) | 5.98 (5.93-6.03) | −26 (−40 to −9) |
aRelative accuracy from observed recontacted cases following a clinical follow-up.